Screener
Bio-Techne TECH Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | March 31, 2026 / (unaudited) | June 30, 2025 |
|---|---|---|
| Trade accounts payable | $23,490 | $25,311 |
| Salaries, wages and related accruals | 54,429 | 65,791 |
| Accrued expenses | 17,682 | 25,663 |
| Contract liabilities | 38,433 | 32,571 |
| Income taxes payable | 2,971 | 10,770 |
| Operating lease liabilities - current | 14,181 | 14,098 |
| Other current liabilities | 2,092 | 1,645 |
| Total current liabilities | 153,278 | 175,849 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's deferred revenue?
- Bio-Techne (TECH) reported deferred revenue of $38.43M in Q1 2026.
- How has Bio-Techne's deferred revenue changed year-over-year?
- Bio-Techne's deferred revenue increased by 19.1% year-over-year, from $32.27M to $38.43M.
- What is the long-term trend for Bio-Techne's deferred revenue?
- Over 4 years (2021 to 2025), Bio-Techne's deferred revenue has grown at a 14.4% compound annual growth rate (CAGR), from $19M to $32.57M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Bio-Techne's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude